San Diego-based Ceregene, which is developing gene therapy treatments for Parkinson’s and other ailments, says it is getting $2.5 million from The Michael J. Fox Foundation for Parkinson’s Research. The company says it is conducting a mid-stage study that aims to deliver the neurotrophic factor neurturin to improve the status of degenerating neurons in the brain. Ceregene says its venture investors include Alta Partners, MPM Capital, Investor Growth Capital, Hamilton BioVentures and California Technology Partners. Another investor, BioSante Pharmaceuticals (NASDAQ: [[ticker: BPAX]]), acquired its position following its merger with Cell Genesys last October.